The Latest Cardiac and Vascular News
Pharmaceutical expert and Chairman of PTC Therapeutics joins other biotech leaders as Independent Director Westport, CT, May 07, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc. Mr. Schmertzler has been the Chairman of […]
Westport, CT, May 01, 2020 (GLOBE NEWSWIRE) — Clinical support staff to return to perform elective procedures at Texas Cardiac Arrhythmia Institute as of May 4, 2020 Company reconfirms its commitment to commercial installations this year BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing […]
Westport, CT, April 21, 2020 (GLOBE NEWSWIRE) — Former senior executive at AstraZeneca and pharmaceutical industry expert to join as Independent Director The Company is developing Vicromax(tm) – a broad-spectrum orally administered anti-viral candidate for COVID-19 Upon receipt of FDA approval, Phase II clinical trial is planned to be conducted at Mayo Clinic BioSig Technologies, Inc. […]
Former Chief Medical Officer of Celgene to lead development of Vicromax(tm), a novel broad-spectrum anti-viral agent that may treat COVID-19 Westport, CT, March 31, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it appointed Jerome Zeldis, […]
One of the nation’s leading cardiologists and Medical Director of UHealth Cardiology to advise on clinical practices Westport, CT, March 10, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range […]
New research project to focus on development of technological solutions for sympathetic nervous system disease Westport, CT, March 04, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG […]
Westport, CT, Feb. 25, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the closing and funding of its previously announced “best efforts” […]
Westport, CT, Feb. 21, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has agreed to sell 2,500,000 shares of its […]
WESTPORT, Feb. 19, 2020 (GLOBE NEWSWIRE) — Commercialization and install plan ahead of schedule Installations at new centers are driving patient enrollments and clinical data collection BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full […]
Westport, CT, Jan. 14, 2020 (GLOBE NEWSWIRE) — Company allowed a fifth utility patent Claims address methods for removing voltage offset from biomedical signals Eleven additional patent applications covering PURE EPTM System are currently pending BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed […]
